9 results about "Synovial sarcoma" patented technology

This invention discloses the application of arginine-depleted engineered bacteria for the treatment of soft tissue sarcomas, including preliminary validation, obtaining qualified engineered bacteria SGR1, obtaining drug compositions and regimens, experimental conclusions, and clinical application promotion. During use, clinical soft tissue sarcoma samples are collected, including undifferentiated pleomorphic sarcoma, synovial sarcoma, and liposarcoma. Immunohistochemistry (IHC) is used to detect ASS1 protein expression, qPCR is used to detect ASS1 gene transcription levels, and the proportion of ASS1 deletion / low expression is statistically analyzed. Arginine auxotrophic sarcoma subpopulations are confirmed based on literature. Cells are cultured in arginine-containing or arginine-free media, and cell viability, colony formation, cell cycle, and apoptosis are detected. The sensitivity of ASS1-deficient cells to arginine deprivation is verified, and therapeutic targets are identified. The enzyme activity, substrate specificity, and immunogenicity of human ARG I / II, mycoplasma ADI, and Pseudomonas ADI are compared. High-activity, low-immunogenic enzymes or enzyme combinations (such as human ARG I + microbial ADI) are selected, and site-directed mutagenesis or codon optimization is performed on microbial ADI to increase expression levels.

The invention discloses a construction method of a synovial sarcoma tumor ball vascular induction model, the model and application of the synovial sarcoma tumor ball vascular induction model. The construction method of the synovial sarcoma tumor sphere vascular induction model comprises the following steps: S1, suspension culture of synovial sarcoma organs; and S2, constructing a synovial sarcoma tumor ball vascular induction model based on the culture chip. When the synovial sarcoma organ is cultured, the synovial sarcoma primary tissue is cultured in a suspension culture mode, and the method not only can improve the proliferation speed of the synovial sarcoma organ, the cell growth state is better, the activity is higher, but also has the advantage of simplicity in operation. Besides, the synovial sarcoma tumor sphere vascular induction model is constructed based on the culture chip, and the model can simulate tumor microenvironment more truly, has tumor-related fibroblast and vascular components, and provides more clinical drug sensitivity test results.

Provided herein are methods and compositions for treating cancer. In some cases, the cancer comprises soft tissue sarcoma, such as synovial sarcoma. In some cases, the treatment comprises administering a therapeutically effective amount of an SS18-SSX fusion protein inhibitor to the subject. In some cases, the treatment comprises administering a therapeutically effective amount of SUMO2 inhibitor to the subject. The subject can be a pediatric subject or an adult subject.

The present invention is based, in part, on the identification of a minimal region of the SS18-SSX fusion oncoprotein that mediates a direct, high-affinity interaction between the mSWI / SNF complex and the nucleosome acidic patch, and methods and agents of modulating the interaction between the SS18-SSX fusion protein and H2A K119Ub-marked nucleosomes to treat synovial sarcoma.

The application provides an application of auro-thio-pan in preparation of a drug for treating a USP6 gene rearrangement and abnormal activation disease, and the auro-thio-pan is a lipophilic gold-based compound. Researches of the application show that in addition to the USP6 gene rearrangement disease, tumors such as osteosarcoma, RUNX1 gene rearrangement and CBFbeta gene rearrangement leukemia, synovial sarcoma and the like also have abnormal activation of USP6, and are clinical application scenarios of USP6 inhibitors. It is further found that the compound auro-thio-pan can effectively combine with a catalytic domain of USP6 and inhibit the deubiquitination enzyme activity of USP6, and inhibit the growth of RUNX1 rearrangement tumors at the cell and animal levels. The application opens up a new direction for the development of a drug for treating the USP6 gene rearrangement and abnormal activation tumor and the like, and expands the application range of auro-thio-pan in the treatment of clinical diseases, and provides a possibility for improving the prognosis and survival of corresponding clinical disease patients.

The present invention provides a compound of Formula I, a salt thereof, or a solvate thereof, as described herein, the composition is used for treating MYC positive cancers including lung cancer, leukemia, breast cancer, myeloproliferative diseases, colorectal cancer, medulloblastoma, kidney cancer, hepatocellular cancer, melanoma, ovarian cancer, prostate cancer, esophageal adenocarcinoma, liposarcoma, esophageal squamous carcinoma, gastrointestinal stromal tumor, glioma, mucus fibrosarcoma, smooth muscle sarcoma, neuroblastoma, synovial sarcoma, mesothelioma, and the like. Gastric cancer, thyroid cancer, lymphoma, osteosarcoma, rhabdomyosarcoma, fibrosarcoma, epithelial cancer and neurological cancer.

The invention relates to the technical field of medicines, in particular to application of a small molecule compound A-485 in preparation of a medicine for treating synovial sarcoma. According to the invention, through high-throughput transcriptome sequencing detection, it is proved that the small molecule A-485 can inhibit gene expression disorder caused by oncogenic protein SS18-SSX1 / 2 / 4; a tumor formation drug delivery experiment of the synovial sarcoma cell line HS-SY-II in a mouse shows that the small molecule A-485 can inhibit the tumor formation capability of the synovial sarcoma cell line. The small molecule A-485 can effectively inhibit the development of the synovial sarcoma induced by the carcinogenic protein SS18-SSX1 / 2 / 4, so that an application technical scheme of the small molecule A-485 in preparation of the medicine for treating the development of the synovial sarcoma is provided. The scheme provided by the invention provides a new way for inhibiting the development of synovial sarcoma.

The invention relates to the technical field of biological medicine, in particular to an identification method of circSS18R-loop in synovial sarcoma and application of the identification method. Comprising the following steps: identifying circSS18R-loop formed by circular RNA circ0108126 of synovial sarcoma, wherein the nucleotide sequence of the circSS18R-loop is as shown in SEQ ID NO: 1. According to the invention, the method comprises the following steps: CUTamp; the TAG is combined with a qPCR (quantitative polymerase chain reaction) technology to identify the existence of circSS18R-loop in a synovial sarcoma cell line HS-SY-II for the first time; it is found for the first time that the circular circ0108126 can promote proliferation, migration and invasion of synovial sarcoma cells and inhibit apoptosis, and deeper cognition and a new thought are brought to a molecular mechanism for regulating synovial sarcoma through circular RNA.

The invention relates to a synovial sarcoma three-dimensional model and a construction method and application thereof. The construction method comprises the following steps: extracting synovial sarcoma cells; performing suspension culture on synovial sarcoma organs; performing three-dimensional culture on synovial sarcoma organs; wherein a culture medium used in the three-dimensional culture of the synovial sarcoma organoid is a mixed culture medium and comprises a synovial sarcoma organoid culture medium and an endothelial cell culture medium. Compared with the prior art, the synovial sarcoma organ culture medium and the endothelial cell culture medium are mixed to form the mixed culture medium for three-dimensional culture, when the synovial sarcoma organ is subjected to three-dimensional culture, the cell survival rate is increased, a three-dimensional model with a vascular structure is formed, and the simulation degree is high.